MedPath

The use of ultraviolet light photochemotherapy Polarised Ultra Violet A [PUVA] in the oral cavity in conjunction with a oral photo-sensitiser [5-methoxypsolaren or 8-methoxypsoralen] for oral graft-versus- host disease [GVHD] in allogeneic bone marrow transplant patients [ABMT].

Phase 1
Recruiting
Conditions
Chronic Oral Graft versus Host Disease
Blood - Haematological diseases
Registration Number
ACTRN12613000330741
Lead Sponsor
St Vincent's Hospital, Sydney
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
25
Inclusion Criteria

Undergone Allogeneic Stem cell transplant with clinical diagnosis of oral GVHD and any degree or oral symptoms leading to pain, discomfort and interfere with oral intake.
Histological confirmation not required.

Exclusion Criteria

Sensivity to sunscreens and photosensitisers.
Known photodermatoses.
Foreseeable intense exposure to solar or UV exposure except study related.
unable to take tablets

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath